Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Kazuyoshi Kato, Yutaka Takahashi, Makio Shozu
Summary: The study investigated the efficacy and toxicity of tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer. Results showed that this tailored dosage chemotherapy was effective and well tolerated in these patients.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Jia Zhu, Juan Wang, Feifei Sun, Zijun Zhen, Tingting Chen, Suying Lu, Junting Huang, Yizhuo Zhang, Xiaofei Sun
Summary: The combination of vincristine, irinotecan, and temozolomide is an effective salvage regimen for relapsed or refractory neuroblastoma patients, achieving a response rate of 69.6% with manageable toxicities.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
M. Haas, D. T. Waldschmidt, M. Stahl, A. Reinacher-Schick, J. Freiberg-Richter, L. Fischer von Weikersthal, F. Kaiser, S. Kanzler, N. Frickhofen, T. Seufferlein, T. Dechow, R. Mahlberg, P. Malfertheiner, G. Illerhaus, S. Kubicka, A. Abdul-Ahad, R. Snijder, S. Kruger, C. B. Westphalen, S. Held, M. Von Bergwelt-Baildon, S. Boeck, V Heinemann
Summary: This study evaluated the combination of gemcitabine and afatinib versus gemcitabine alone in treating metastatic pancreatic cancer. The addition of afatinib did not improve treatment efficacy and was found to be more toxic. The BOTh(C)(TM) methodology provided detailed insights into treatment-related adverse events during the study period.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Nutrition & Dietetics
Susie Youn, Angela Chen, Vincent Ha, Carole Chambers, Dean T. Eurich, Michael McCall, Michael B. Sawyer
Summary: The study found that adjusting nab-paclitaxel doses based on muscle mass can predict the risk of chemotherapy toxicity. Factors like BMI, body surface area, and initial drug doses did not significantly impact toxicity occurrence.
CLINICAL NUTRITION
(2021)
Article
Oncology
Kenneth H. Yu, Andrew E. Hendifar, Olatunji B. Alese, Amber Draper, Maen Abdelrahim, Ethan Burns, Gazala Khan, Paul Cockrum, Rachel H. Bhak, Catherine Nguyen, Maral DerSarkissian, Mei Sheng Duh, Nathan Bahary
Summary: This study retrospectively reviewed cases from six academic centers in the US, finding that patients treated with NAPOLI-1-based liposomal irinotecan regimens had similar outcomes and efficacy despite being older and having poorer performance status compared to trial patients. Additionally, the use of liposomal irinotecan in the 3L+ setting provided clinical benefit where no approved treatment exists.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Esther N. Pijnappel, Nienke P. M. Wassenaar, Oliver J. Gurney-Champion, Remy Klaassen, Koen van der Lee, Marjolein C. H. Pleunis-van Empel, Dick J. Richel, Marie C. Legdeur, Aart J. Nederveen, Hanneke W. M. van Laarhoven, Johanna W. Wilmink
Summary: The combination of LDE225 with gemcitabine and nab-paclitaxel was well-tolerated and effective in patients with metastatic PDAC, especially in those with poor baseline tumor perfusion. These results suggest a potential clinical benefit of this combination therapy in patients who have received prior FOLFIRINOX treatment.
Review
Multidisciplinary Sciences
Yoon Suk Lee, Jong-chan Lee, Jae-Hyeong Kim, Jaihwan Kim, Jin-Hyeok Hwang
Summary: The treatment outcomes of FOLFIRINOX and GNP as first-line chemotherapy regimens for metastatic pancreatic cancer vary between Western and Asian subgroups, with Western patients showing higher survival benefit from FOLFIRINOX and Asian patients showing higher survival benefit from GNP.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Ghazal Tansir, Sameer Rastogi, Akash Kumar, Adarsh Barwad, Asit R. Mridha, Ekta Dhamija, Shamim A. Shamim, Sushma Bhatnagar, Sandeep Bhoriwal
Summary: This study evaluates the efficacy, tolerability, and quality of life with the combination of gemcitabine and docetaxel in advanced, relapsed synovial sarcoma patients. The therapy produced clinically meaningful outcomes and met the primary endpoint of 3-month progression-free rate. These results should encourage further studies.
Article
Oncology
Kenneth H. Yu, Paul Cockrum, Andy Surinach, Neil Lamarre, Shu Wang, Eileen M. O'Reilly
Summary: This retrospective study found that prior exposure to irinotecan did not have a significant impact on clinical outcomes in patients treated with liposomal irinotecan. These findings are important in informing decisions about the use of liposomal irinotecan therapy following prior irinotecan exposure.
Article
Oncology
In Sil Choi, Ki Hwan Kim, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Hyun Park, Yu Jung Kim, Jin-Soo Kim, Jee Hyun Kim, Jin Won Kim
Summary: The study found that in the second-line treatment of biliary tract cancer, irinotecan/5-fluorouracil (mFOLFIRI) was not superior to oxaliplatin/5-fluorouracil (mFOLFOX), but both showed comparable efficacy and tolerability. Adverse events differed between the two treatment arms.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Jung Hyun Jo, Dawoon E. Jung, Hee Seung Lee, Soo Been Park, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Sangsook Cho, Si Young Song
Summary: This phase I/II study evaluated the safety and efficacy of a new HDAC inhibitor called ivaltinostat in combination with gemcitabine and erlotinib for advanced PDAC. The study found that this combination therapy showed potential as a treatment option for PDAC.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Soenke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Summary: This study aims to investigate whether reduced dose GemNab is superior to full dose Gem in patients with resectable pancreatic cancer. The study will explore various endpoints including progression-free survival, overall survival, overall response rate, quality of life, toxicity, and rate of hospitalizations. The correlation between blood inflammatory markers, circulating tumor DNA, tissue biomarkers, and chemotherapy resistance will also be studied, along with measures of frailty to assess personalized treatment allocation or interventions.
Article
Oncology
Inna M. Chen, Julia S. Johansen, Susann Theile, Jessica X. Hjaltelin, Sif Novitski, Soren Brunak, Jane P. Hasselby, Gro L. Willemoe, Torben Lorentzen, Kasper Madsen, Benny Jensen, Eva E. Wilken, Poul Geertsen, Claus Behrens, Christian Nolsoe, Kirstine L. Hermann, Inge Marie Svane, Dorte Nielsen
Summary: This study evaluated the clinical benefit of nivolumab in combination with stereotactic body radiotherapy (SBRT) with or without ipilimumab in patients with refractory metastatic pancreatic cancer. The results demonstrated clinically meaningful antitumor activity and favorable safety profiles in patients receiving nivolumab combined with ipilimumab and SBRT.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Seo Yeon Kim, Min Jeong Jo, Moon Sup Yoon, Chae Eun Jin, Yu Been Shin, Jae Min Lee, Hee Ji Shin, Joon Gyo Oh, Jae Min Cho, Hyunjun Kim, Hyunjin Park, Yong-Won Choi, Chun-Woong Park, Jin-Seok Kim, Dae Hwan Shin
Summary: This study developed a drug delivery strategy for pancreatic ductal adenocarcinoma using a thermosensitive gel, which successfully achieved controlled release of drugs based on the researchers' tolerance settings. The gel consisted of gemcitabine (GEM) and the mammalian TOR (mTOR) inhibitor rapamycin (RAPA), demonstrating good cytotoxicity and anti-tumor effects in in vitro and in vivo experiments.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Medicine, General & Internal
Hung-Yuan Yu, Chun-Yang Lee, Le-Gin Lin, Yee Chao, Chung-Pin Li
Summary: This study evaluated the effectiveness and safety of a nanoliposomal irinotecan (nal-IRI) + 5-FU/LV regimen for patients with metastatic pancreatic cancer and treatment failure with gemcitabine-based therapy. The results showed that the regimen was effective and tolerable at reduced doses in controlling the disease.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
(2022)